Health for all, Hunger for none
Financial Results for FY 2024-25
Bayer CropScience Limited Reports Q4 & Annual Results
Mumbai, May 26, 2025: Bayer CropScience Limited (BSE: 506285) on Monday announced its results for the financial year (FY) and quarter ended March 31, 2025.
In FY 2024-25, the Company’s Revenue from Operations increased to ₹54,734 million, compared to ₹51,062 million in the previous year. Profit Before Tax stood at ₹7,074 million, compared to ₹9,414 million in the previous year.
In Q4 of FY 2024-25, the Company registered Revenue from Operations of ₹10,464 million, compared to ₹7,923 million in the corresponding quarter of the previous year. Profit Before Tax for the quarter stood at ₹1,679 million, compared to ₹1,054 million in the corresponding quarter of the previous year.
Commenting on the quarterly results, Simon Wiebusch, Vice Chairman, Managing Director and CEO, BCSL said, “In Q4, our Revenue from Operations grew by 32 percent over the previous year, driven by strong performance in spring corn and by both strong performance and double-digit liquidation growth in the crop protection portfolio. The promotional investments made in the previous quarter generated significant returns. Quarter-on-quarter deviations reflect the realities of our agriculture. Our focus on liquidation-led channel management aligns with market realities and demonstrates our commitment to delivering continuous value.”
Speaking on the FY results, Vinit Jindal, Executive Director and Chief Financial Officer, BCSL, said, "Our Revenue from Operations grew by 7 percent for the full year, demonstrating our resilience amid challenges like unpredictable monsoons and competitive pressures. Despite strict cost management, higher input costs, provisions for doubtful receivables, and continued investments to expand Bayer’s reach among farmers, influenced our bottom line. Strategic investments drove operating costs. Moving forward, we will maintain focus on these initiatives and adapt our strategies to meet evolving market and stakeholder needs. The Board of Directors has recommended a final dividend payment of ₹35/- per equity share of ₹10/- each for the financial year ended March 31, 2025, subject to shareholders’ approval.”
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2024, the Group employed around 93,000 people and had sales of 46.6 billion euros. R&D expenses amounted to 6.2 billion euros. For more information, go to www.bayer.com.
Snigdha Vishal
Communications, Bayer CropScience Limited
E-mail: snigdha.vishal@bayer.com
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports, which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
